ASX Linkedin Twitter               

 

Analyst Coverage 2017

Bell Potter
10 July 2017
Celgene Enters Immuno-Oncology Race

Bell Potter
30 June 2017
Stock Picks for Financial Year 2017/18

Bell Potter
14 June 2017
CAVATAK Remains on Track – ASCO Wrap

Bell Potter
24 May 2017
Combination Therapy Trials Continue to Raise The Bar

Edison
19 April 2017
Cavatak/Yervoy combo enters the spotlight

Bioshares Edition 691
7 April 2017
AACR – Viralytics Data Update

Roth Capital Partners
5 April 2017
Standing Out from the Oncolytic Virus Pack at AACR 2017

Bell Potter
4 April 2017
CAPRA – Something is Going On

Bell Potter
30 March 2017
Important Clinical Trial Update This Weekend

Bioshares Edition 689
24 March 2017
Viralytics Continues to Build CAVATAK Data

Edison
9 March 2017
Cavatak combo data at AACR next month

Roth Capital Partners
31 January 2017
A Dash of Virus Completes the Immunotherapy Cocktail

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).